DX方案与XELOX方案一线治疗晚期胃癌疗效比较

doi:10.3969/j.issn.1002-3070.2010.01.016

实用肿瘤学杂志 ›› 2010, Vol. 24 ›› Issue (1): 62-63.doi: 10.3969/j.issn.1002-3070.2010.01.016

DX方案与XELOX方案一线治疗晚期胃癌疗效比较

刘磊¹, 顾曼玲²

1.作者单位:哈尔滨医科大学附属肿瘤医院(哈尔滨 150081);
2.哈尔滨市红十字中心医院

收稿日期:2009-05-13 出版日期:2010-02-28 发布日期:2015-01-23
作者简介:刘磊,女,(1982-),硕士,住院医师,从事消化道肿瘤的内科治疗

Clinical comparison of docetaxel/capecitabine and oxaliplatin/capecitabine in treating advanced gastric cancer

LIU Lei¹, GU Manling²

1.The Affiliated Tumor Hospital of Harbin Medical University,Harbin 150081;
2.The Red Cross Central Hospital of Harbin,Harbin 150081

Received:2009-05-13 Online:2010-02-28 Published:2015-01-23

摘要/Abstract

摘要： 目的观察DX方案(多西紫杉醇联合卡培他滨)与XELOX方案(草酸铂联合卡培他滨)治疗晚期胃癌的客观疗效和毒性反应。方法 DX方案组21例晚期胃癌患者接受多西紫杉醇75mg/m² d1卡培他滨每日1700mg/m²,分2次口服,d1-14,21d为1周期,疗程2-6周期。XELOX方案组20例晚期胃癌患者接受奥沙利铂130mg/m² dl,卡培他滨每日1700mg/m²,分2次口服,d1-d14,21d为1周期,疗程2-6周期。结果 DX方案组总有效率为52.4%常见的毒性反应为中性粒细胞减少性发热、脱发、腹泻及口腔黏膜炎发生率较高;XELOX方案组总有效率为50.0%,常见的毒性反应为手足综合征和周围神经毒性反应等。结论 DX方案和XELOX方案均为治疗进展期胃癌较好的方案,其中XELOX方案副反应较低可提高患者的生存质量,毒副作用能耐受,更适合老年体弱病人。

Abstract: Objective To evaluate the objective response rate,time to progression(TTP)and toxicity between Docetaxel/Capecitabine and Oxaliplatin/Capecitabine in the treatment of advanced gastric cancer.Methods 21 patients with advanced gastric cancer were administrated with Docetaxel 75mg/m²(d1),Capecitabine 1700mg/m²/d divided in two daily doses given from d1 to d14.The cycles were repeated every 21 days.All patients received two to six cycles.The other 20 patients with advanced gastric cancer were administrated with Oxaliplatin 130mg/m²,(d1)combined Capecitabine 1700mg/m²/d divided in two daily doses given from d1 to d14.All patients received two to six cycles.The treatment was finished after 2 recycles.Results The total response rate in Docetaxel/Capecitabine was 52.4 %,the most common adverse effects were febrile neutropeni,neutropenia,alopecia,diarrhea and inflammation of oral mucosa.The response rate in XELOX was 50.0 %,the most common adverse effects were hand foot syndrome and peripheral neuropathy.Conclusion The Oxaliplatin/Capecitabine regimen offers a better therapeutic option in patients with advanced gastric cancer.

中图分类号:

R735.2

刘磊, 顾曼玲. DX方案与XELOX方案一线治疗晚期胃癌疗效比较[J]. 实用肿瘤学杂志, 2010, 24(1): 62-63.

LIU Lei, GU Manling. Clinical comparison of docetaxel/capecitabine and oxaliplatin/capecitabine in treating advanced gastric cancer[J]. PRACTICAL ONCOLOGY JOURNAL, 2010, 24(1): 62-63.

[1]	孟海,杜观祥,朱利玲,汤琪云. WEE1在胃癌组织中的表达及对患者预后的影响[J]. 实用肿瘤学杂志, 2019, 33(3): 239-243.
[2]	刘佳音,燕飞虎,张艳桥. 凋亡基因Caspase3和Caspase7单核苷酸多态性与胃癌遗传易感性研究[J]. 实用肿瘤学杂志, 2019, 33(3): 250-255.
[3]	张宝综述, 郑志超校审. 进展期胃癌淋巴结清扫研究进展[J]. 实用肿瘤学杂志, 2019, 33(1): 78-81.
[4]	唐淑丽, 何匡邦, 张纯慧, 程佳楠, 张艳桥. 胃癌组织中miR-320a和CYLD的表达及与临床病理特征及预后的关系[J]. 实用肿瘤学杂志, 2018, 32(6): 538-544.
[5]	刘玉, 王子安. 原发性胃肠道恶性淋巴瘤术后生存期的影响因素及TNM分期对远期生存的预测价值分析[J]. 实用肿瘤学杂志, 2018, 32(4): 315-319.
[6]	姚强, 王宽, 薛英威. SRC1在胃癌中的表达及其与预后的关系[J]. 实用肿瘤学杂志, 2018, 32(2): 97-102.
[7]	张纯慧, 刘霞, 徐京京, 周艳华, 赵娟, 李志伟, 张艳桥. 633例胃癌患者临床病理特征及生存分析[J]. 实用肿瘤学杂志, 2017, 31(5): 396-404.
[8]	张锡,陈力,薛英威. 外周血中CEA和CA19-9的表达水平在进展期胃癌中的预后价值[J]. 实用肿瘤学杂志, 2017, 31(4): 342-347.
[9]	李恩就, 胡菂菂, 龚志军, 卿笃桔, 刘虹, 黎飞. 血清胃蛋白酶原联合Ca724在胃癌患者中的诊断及预后价值[J]. 实用肿瘤学杂志, 2017, 31(1): 18-22.
[10]	陈力, 张玉新, 左艳娇, 马菲, 宋洪江, 薛英威. SOX和XELOX在进展期胃癌新辅助化疗中的临床疗效比较[J]. 实用肿瘤学杂志, 2017, 31(1): 23-30.
[11]	毛维, 陈青娟, 司小敏, 张消, 蒋成. 分泌超高血清AFP胃肝样腺癌1例并文献复习[J]. 实用肿瘤学杂志, 2017, 31(1): 39-42.
[12]	李汝东, 侯家晨, 崔晓晗综述, 王旭东审校. 胃肝样腺癌诊疗现状及进展[J]. 实用肿瘤学杂志, 2017, 31(1): 53-56.
[13]	彭文苗，张志敏，胡萌，余丽芳，章必成，饶智国，秦传蓉. RPL23-siRNA干扰片段的构建及筛选[J]. 实用肿瘤学杂志, 2016, 30(6): 487-491.
[14]	徐俊, 张恩勇, 罗天航, 薛绪潮, 崔航天, 方国恩. 早期胃混合型印戒细胞癌的临床病理因素分析[J]. 实用肿瘤学杂志, 2016, 30(5): 414-419.
[15]	庞锐,薛英威. 胃癌浸润距离的研究与临床应用[J]. 实用肿瘤学杂志, 2016, 30(4): 314-320.

DX方案与XELOX方案一线治疗晚期胃癌疗效比较

Clinical comparison of docetaxel/capecitabine and oxaliplatin/capecitabine in treating advanced gastric cancer

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价